PPT-Telaprevir in Treatment

Naïve GT1 ADVANCE Study 108 Phase 3 Treatment Naïve Jacobson IM et al N Engl J Med 2011364240516 Source Jacobson IM et al N Engl J Med 2011364240516 Telaprevir for TreatmentNaïve HCV Genotype . In the biological treatment of wastewaters aeration is essential to raise the dissolved oxygen DO level to allow aerobic bacteria to work and reduce the pollution load BOD of the waste and thus to improve water quality The rate of oxygen transfer in ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR + SMV placebo + PEG-IFN + RBV. Randomisation*. 1 : 1. Double-blind. ≥ 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Null or partial responders to . Department of Medicine. University of Toronto. Complicated cases. CASE 1 . 54 . yr. /o. man . HIV positive 8 . yrs. ago. Tenofovir. /FTC/RTV/. Atazanavir. . x 4 . yrs. Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . Naïve GT-1. ILLUMINATE (Study 111). Phase . 3. Treatment. . Naïve. Sherman KE, et. al. N . Engl. J Med. 2011;365:1014-24.. Source: Sherman . KE, et. al. . N . Engl. J Med. 2011;365:1014-24.. Telaprevir for Treatment-Naïve HCV Genotype . Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. Mark Sulkowski, . MD. Professor of Medicine. Medical Director, Viral Hepatitis Center . Johns Hopkins University. Baltimore Maryland USA. Liver disease is the second leading specific causes of death amongst HIV-positive individuals in the D:A:D study. Dr. Sonalika’s Eye Clinic provide the best Low vision aids treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Paediatric ophthalmology treatment, Paediatric eye checkup treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Phaco surgery treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Conjunctivitis (Pink Eye) treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri